Actionable news
0
All posts from Actionable news
Actionable news in VRX: VALEANT PHARMACEUTICALS INTERNATIONAL,

Valeant (VRX) Stock Higher Ahead of Anticipated FDA Approval

NEW YORK (TheStreet) -- Shares of Valeant Pharmaceuticals (VRX) are gaining 4.33% to $23.85 in early-afternoon trading on Monday ahead of the FDA's July 19 Prescription Drug User Fee Act (PDUFA) date for the new drug application of Relistor oral in the treatment of opioid-induced constipation.

"Following the FDA's delay in PDUFA date, we remain confident that Oral Relistor should see approval in or around its PDUFA date," RBC Capital Markets wrote in a note last week.

Valeant has another upcoming PDUFA date on July 21 for the new drug application of Vesneo (lantanoprostene bunod) in the treatment of elevated intraocular pressure.

Vesneo could see a delay in its PDUFA date by three months, but should be approved by October, according to RBC.

SMALL INVESTMENT, BIG POTENTIAL. ...


More